Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on April 16, 2003, to report on the results of its Phase II clinical trial for AXOKINE®. The trial evaluated AXOKINE®'s efficacy in promoting weight loss among overweight and obese individuals diagnosed with type 2 diabetes. The announcement of these trial results was made via a press release on April 14, 2003, and is included as an exhibit to this filing. Investors should monitor future filings for further developments regarding AXOKINE® and its potential implications for the company's product pipeline and future revenue streams.
Key Highlights
- 1Regeneron Pharmaceuticals announced Phase II trial results for AXOKINE® on April 14, 2003.
- 2The trial focused on weight loss in overweight and obese patients with type 2 diabetes.
- 3The press release detailing these results is filed as an exhibit (Exhibit 99a).
- 4The filing date for this 8-K report is April 16, 2003.
- 5This report falls under Item 5 (Other Events) and Item 7 (Exhibits) of the 8-K form.